Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study

Abstract Background PROMISE-2 was a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of repeat intravenous (IV) doses of the calcitonin gene-related peptide–targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with chro...

Full description

Bibliographic Details
Main Authors: Stephen Silberstein, Merle Diamond, Nada A. Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith
Format: Article
Language:English
Published: BMC 2020-10-01
Series:The Journal of Headache and Pain
Subjects:
Eptinezumab
Chronic migraine
Efficacy
Safety
Online Access:http://link.springer.com/article/10.1186/s10194-020-01186-3

Internet

http://link.springer.com/article/10.1186/s10194-020-01186-3

Similar Items